Together, these results point to a clinically meaningful synergy between pelareorep and checkpoint inhibitors like atezolizumab." In pancreatic cancer, pelareorep has also demonstrated strong ...

Patients with HCC at high risk of recurrence after resection or local ablation were randomly assigned to receive either atezolizumab plus bevacizumab or active surveillance in the IMbrave 050 study.

On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...

Patients received oral cabozantinib 40 mg once daily and intravenous atezolizumab 1,200 mg once every 3 weeks. The primary end point was objective response rate (ORR), as assessed by the investigator ...

Findings from a phase 1b/2 study showed improvement in overall survival with amezalpat plus atezolizumab/bevacizumab vs atezolizumab/bevacizumab alone. The Food and ...

In this article, we investigate physiological processes during the acute phase of enzymatic ECM removal. We found that hyaluronidase, an ECM removal agent, triggers simultaneous membrane ...